Rx00152 - Mesalamine


Name:
Mesalamine
Rx ID:
Rx00152
Validation Level:
Phenomic Similarity:
0.544
Reference ID:
DB00244
Primary Indications:
Active mild ulcerative colitis; active moderate ulcerative colitis; pediatric ulcerative proctitis
Orphan Indications:
No annotated orphan indications.
Rare Indications:
No annotated rare indications.
Common Indications:
Adult ulcerative colitis; active ulcerative proctitis
Drug Interactions:
Azathioprine; Mercaptopurine Tioguanine;
Food Interactions:
Take without regard to meals.

Interactive 3D Model

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00152
Primary Indication
Secondary Indication

Visualize Chemical Properties

Select x-axis

Select y-axis

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
pediatric ulcerative proctitis active ulcerative proctitis 1357 1357 1357 2973.415 0 0.0
active mild ulcerative colitis adult ulcerative colitis 9520 9520 9520 423.837 0 0.0
active moderate ulcerative colitis adult ulcerative colitis 9520 9520 9520 423.837 0 0.0

Chemical, Pharmacological and Biological Annotations


ATC Code:
A07EC02
Brands:
Asacolitin; Claversal; Fisalamine; Lixacol
Category:
Anti-Inflammatory Agents, Non-Steroidal
ChEBI ID:
6775
PubChem ID:
4075
KEGG Drug ID:
D00377
SMILE:
NC1=CC(C(O)=O)=C(O)C=C1
InChI:
1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
Classification:
Kingdom:
Organic Compounds
Superclass:
Benzenoids
Class:
Benzene and Substituted Derivatives
Subclass:
Benzoic Acid and Derivatives
Indication:
For the treatment of active ulcerative proctitis.
Pharmacodynamics:
Mesalazine (INN, BAN), also known as Mesalamine (USAN) or 5-aminosalicylic acid (5-ASA), is an anti-inflammatory drug used to treat inflammation of the digestive tract (Crohn's disease) and mild to moderate ulcerative colitis. Mesalazine is...
Click to show more...
Description:
An anti-inflammatory agent, structurally related to the salicylates, which is active in inflammatory bowel disease. It is considered to be the active moiety of sulphasalazine. (From Martindale, The Extra Pharmacopoeia, 30th ed)
Mechanism:
Although the mechanism of action of mesalazine is not fully understood, it appears to be topical rather than systemic. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and thro...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Human Intestinal Absorption:
+
Blood Brain Barrier:
-
Caco-2 permeable:
-
P-glycoprotein substrate:
Non-substrate
P-glycoprotein inhibitor I:
Non-inhibitor
P-glycoprotein inhibitor II:
Non-inhibitor
Renal organic cation transporter:
Non-inhibitor
CYP450 2C9 substrate:
Non-inhibitor
CYP450 2D6 substrate:
Non-inhibitor
CYP450 2C19 substrate:
Inhibitor
CYP450 inhibitory promiscuity:
Low CYP Inhibitory Promiscuity
Ames test:
Non AMES toxic
Carcinogenicity:
Non-carcinogens
Biodegradation:
Ready biodegradable
Rat acute toxicity:
1.7065 LD50, mol/kg
hERG inhibition (predictor I):
Weak inhibitor
hERG inhibition (predictor II):
Non-inhibitor

Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org